CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc. (Nasdaq: PBAX) is the post-merger public company formed through the combination of Phoenix Biotech Acquisition Corp, a blank-check vehicle sponsored by Phoenix Biotech Sponsor LLC that completed its initial public offering in 2021 targeting the biotechnology and life sciences sector, and Cero Therapeutics, Inc., a developer of chimeric engulfment receptor T-cell therapies for solid tumor oncology. The company filed a 424B3 prospectus supplement on May 15, 2026, under accession number 0001213900-26-057853, reflecting continued post-combination public disclosure obligations on Nasdaq. To access full filing history, deal timelines, and real-time SPAC data on PBAX and the broader market, sign up for full data at SpacDesk.